Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Monitoring ovarian function in oncology studies

ASCO 2024

31 May - 4 Jun 2024

Published: 1 Jun 2024

Views: 75

Rating:

Save

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA

Dr Loggers talks to ecancer at ASCO 2024 about results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumours.

In DeFi, 75% of ‘females of reproductive potential’ treated with nirogacestat experienced ovarian toxicity. Most events resolved, including in 100% who stopped treatment for any reason, suggesting ovarian toxicity with nirogacestat is transient.

Though initiated prior to the ASCO guidance, ovarian toxicity assessments in DeFi generally align with and support the use of both clinical measures and hormone biomarkers in oncology clinical trials.

Related Videos

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond...

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

The advancements in radiotherapy for breast cancer patients

Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia

The advancements in radiotherapy for breast cancer patients ( Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia )

Moving to the future: Artificial intelligence in surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Moving to the future: Artificial intelligence in surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

More from ecancer